An incident during testing in 2015 on the KC-46A Pegasus tanker has led The Boeing Company (NYSE:BA) to file suit against two of its suppliers in California. The Boeing Company is suing Able Aerospace Adhesives and AlfaKleen Chemical Labs over claims of mislabeled chemicals that damaged the aircraft’s refueling system and delayed the tanker’s first flight by a month, the Seattle Times reported. The suit, filed in federal court in Santa Ana, California, seeks $10 million in damages from the companies and also refers to 10 other yet-to-be-identified parties the company believes played a role in the manufacturing and mislabeling of the chemical. Boeing is building and testing the militarized 767 jets in Washington state. The tanker can refuel military fighter jets, bombers, helicopters and freighters in the air and carry passengers, medical patients and cargo. The incident that led to the lawsuit happened in July 2015 when the wrong chemical was used during a test of the plane’s fuel system and caused corrosion.
At the movement The Boeing Company (NYSE:BA) is under coverage by number of analysts. Buy rating has been given by 5 analysts to the company stock whereas 3 analysts given UNDERPERFORM rating to stock and 9 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.50 on scale of 1-5. Analysts mean target price for The Boeing Company (NYSE:BA) is $171.70 while their mean recommendation is 2.60 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved down -0.11% to end the day at $175.36. Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as 22.89. The current share price indicate that stock is -0.46% away from its one year high and is moving 61.03% ahead of its 52-week low.
Thomson Reuters Corporation (NYSE:TRI) announced the official opening of Thomson Reuters Labs – Singapore. The Lab will collaborate with the government, customers, tech startups and universities to build partnerships and create innovative products and solutions for professional markets throughout the Asia Pacific region. The Singapore Lab is the first branch in Asia to open as part of Thomson Reuters Labs growing global network, joining locations in Boston, Cape Town, London, Waterloo (Canada) and Zürich. Located in Singapore’s central business district at One Raffles Quay, the Lab opening will be officiated by Sopnendu Mohanty, Chief Fintech Officer, Monetary Authority Singapore (MAS) and will support Thomson Reuters financial & risk, tax & accounting and legal businesses across Asia Pacific. Thomson Reuters Labs enable lean experimentation with advanced data analytics and machine intelligence to solve global challenges for customers. Specifically, the Labs provide capabilities across the many disciplines that constitute data science, delivering data exploration tools, dashboards, visualizations and proof-of-concept applications.
On 22 February 2017, Thomson Reuters Corporation (NYSE:TRI) shares moved to $43.07 after starting the day at $43.48. Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 14 analysts given HOLD rating to the stock. Analyst’s mean target price for TRI is $43.68 while analysts mean recommendation is 2.90.